STIOLTO RESPIMAT offers
unparalleled support for your
patients along their COPD
treatment journey
-
*
Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer lngelheim Pharmaceuticals, Inc. as of 10/08/23. Placement on formulary does not establish clinical comparability of products including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer lngelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.
GET STARTED
STIOLTO RESPIMAT—the fastest-growing LAMA/LABA—is also affordable for patients with COPD1
$0 Co-pay Savings
Eligible patients may pay as little as $0 for a 30- or 90-day supply (1 or 3 inhalers) with the STIOLTO RESPIMAT Savings Card1†
†See Terms and Conditions here.
LAMA, long-acting antimuscarinic agent; LABA, long-acting beta₂-agonist.
GET ACCESS
Unrestricted access
More than 87% of commercial and Medicare Part D patients have unrestricted access* to STIOLTO RESPIMAT1
-
*
Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer lngelheim Pharmaceuticals, Inc. as of 10/08/23. Placement on formulary does not establish clinical comparability of products including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer lngelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.
Prescribing a 90-day supply can save you up to 2 hours every day and make it more likely your patients will be adherent1‡
-
‡
Applies to medications prescribed for various conditions.
Support and tools that help your patients with COPD start and
stay on STIOLTO RESPIMAT
Inhaleability HUB resources that help patients start and stay on treatment:
Local air quality data updated in real time for accuracy
The interactive MyActivity Tracker to help patients set and achieve goals
Tools and other helpful resources
STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray is a combination of tiotropium, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Important Limitations of Use
STIOLTO is NOT indicated to treat acute deterioration of COPD and is not indicated to treat asthma.
Use of a LABA, including STIOLTO RESPIMAT, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma.
STIOLTO is contraindicated in patients with hypersensitivity to tiotropium, ipratropium (atropine derivatives), olodaterol, or any component of this product.
In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also reported in clinical trials with STIOLTO.
WARNINGS AND PRECAUTIONS
LABA as monotherapy (without an ICS), for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, increases the risk of asthma-related hospitalizations.
Do not initiate STIOLTO in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue therapy for acute symptoms. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
STIOLTO should not be used more often or at higher doses than recommended, or with other LABAs as an overdose may result.
If immediate hypersensitivity reactions occur, such as urticaria, angioedema, rash, bronchospasm, anaphylaxis, or itching, discontinue STIOLTO at once and consider alternative treatment. Patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to STIOLTO.
If paradoxical bronchospasm occurs, discontinue STIOLTO immediately and institute alternative therapy.
STIOLTO can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO may need to be discontinued.
Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines.
Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop.
Use with caution in patients with urinary retention especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) should be monitored closely for anticholinergic side effects.
Be alert to hypokalemia and hyperglycemia.
ADVERSE REACTIONS
The most common adverse reactions with STIOLTO (>3% incidence and higher than an active control) were: nasopharyngitis, 12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), and back pain, 3.6% (1.8%/3.4%).
DRUG INTERACTIONS
Use caution if administering adrenergic drugs because sympathetic effects of olodaterol may be potentiated.
Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol.
Use with caution in patients taking non–potassium-sparing diuretics, as the ECG changes and/or hypokalemia may worsen with concomitant beta-agonists.
The action of adrenergic agents on the cardiovascular system may be potentiated by monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval. Therefore, STIOLTO should be used with extreme caution in patients being treated with these drugs. Use beta-blockers with caution as they not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in patients with COPD.
Avoid co-administration of STIOLTO with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.
STIOLTO is for oral inhalation only.
The STIOLTO cartridge is only intended for use with the STIOLTO RESPIMAT inhaler.
Inform patients not to spray STIOLTO into the eyes as this may cause blurring of vision and pupil dilation.
CL-STO-100021 6.5.2019
Please see accompanying full Prescribing Information, Patient Information, and Instructions for Use for STIOLTO RESPIMAT.
REFERENCE
-
Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.